Pusztai L - Search Results

1

Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer.

Pusztai L, Gianni L. Pusztai L, et al. Nat Clin Pract Oncol. 2004 Nov;1(1):44-50. doi: 10.1038/ncponc0025. Nat Clin Pract Oncol. 2004. PMID: 16264799 Review.

2

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Pusztai L, et al. Am J Clin Oncol. 1998 Oct;21(5):442-6. doi: 10.1097/00000421-199810000-00004. Am J Clin Oncol. 1998. PMID: 9781596 Clinical Trial.

3

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

4

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. Oncologist. 2001;6(2):133-46. doi: 10.1634/theoncologist.6-2-133. Oncologist. 2001. PMID: 11306725 Free article. Review.

5

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2001 Sep-Oct;7(5):413-20. Cancer J. 2001. PMID: 11693900

6

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

7

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.

Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2002 Nov-Dec;8(6):461-8. doi: 10.1097/00130404-200211000-00010. Cancer J. 2002. PMID: 12500855

8

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.

Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2003 Jan-Feb;9(1):33-41. doi: 10.1097/00130404-200301000-00007. Cancer J. 2003. PMID: 12602766

9

Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study.

Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Pusztai L, et al. Cancer Genet Cytogenet. 2003 Mar;141(2):148-53. doi: 10.1016/s0165-4608(02)00737-9. Cancer Genet Cytogenet. 2003. PMID: 12606133

10

Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.

Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Zhang F, et al. Among authors: pusztai l. Cancer. 2003 Apr 1;97(7):1758-65. doi: 10.1002/cncr.11245. Cancer. 2003. PMID: 12655533 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

570 results

Search Page

Filters